Removing GALE boosted immune cell killing in colorectal cancer models
The 2 cancer-care developments that matter from the last 3 days, strongest evidence first.
- Removing GALE boosted immune cell killing in colorectal cancer models
- Blocking BAZ2A restored engineered immune cells in mouse kidney cancer
Removing GALE boosted immune cell killing in colorectal cancer models
In lab tests, mouse models and organoids grown from patients’ colorectal cancer, removing GALE helped immune cells kill more tumor cells.
“Together, these findings reveal how nucleotide-sugar metabolism shapes tumor-immune communication through complex N-glycan remodeling and identify GALE and its downstream receptor-ligand interactions as potential therapeutic targets for enhancing Vγ9Vδ2 T cell antitumor activity.”
What this means. Lab or animal research on bowel cancer. Not yet tested as a treatment in people; many lab results never reach patients.
Nature Cancer, 30 Oct 2026 · Translational research (lab work plus patient samples)Blocking BAZ2A restored engineered immune cells in mouse kidney cancer
In mice with renal cell carcinoma, blocking BAZ2A reduced palmitic acid buildup and restored the cancer-killing activity of engineered immune cells.
“These findings reveal an epigenetic-metabolic mechanism of immune resistance and suggest that targeting tumor lipid remodeling represents a therapeutic strategy to overcome CAR-T resistance in solid tumors.”
What this means. Lab or animal research on several cancer types. Not yet tested as a treatment in people; many lab results never reach patients.
Nature Cancer, 30 Oct 2026 · Laboratory or animal-stage researchIndia
- Assam signs Rs 600 crore deal for India's first state-run proton therapy centrehealth.economictimes.indiatimes.com
Worth watching
- Deferred radiotherapy did not lower survival in metastatic nasopharyngeal cancerAmong people whose metastatic nasopharyngeal cancer responded to chemotherapy and immunotherapy, delaying radiotherapy until the cancer grew in the nose or throat did not lower 2-year survival: 97.4% versus 90.1% with immediate radiotherapy.
- Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as CAR T cell target for pediatric solid tumorsPreclinical, laboratory or animal-stage, Nature Communications, 31 Oct 2026
- Tissue architecture and immune niches govern circulating tumour DNA release in colorectal cancerResearch finding, Nature Portfolio, 1 Nov 2026
- Deep learning integration of ultrasound perfusion and stiffness maps predicts tumor response to treatmentResearch finding, Nature Portfolio, 1 Nov 2026